Join us for an exclusive session on CLIPS™ multicycles, a novel class of constrained tricyclic peptides with enormous potential as next-generation peptide therapeutics. Explore how tricyclic peptides replicate key features of antibodies to achieve high-affinity and high-selectivity in target binding with greatly enhanced proteolytic stability as a bonus. Discover how our unique chemistry ensures single-isomer selection early in the screening process, combined with a high-diversity screening method. We will showcase the discovery and optimization of tricyclic peptides against high-value targets, like membrane receptor proteins and monoclonal antibodies. Whether you’re in research, biotech, or pharmaceuticals, learn how high-diversity tricyclic peptide screening might support your drug development projects.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
